Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb This Week: CeGaT, Thermo Fisher Scientific, and OneOme

CeGaT Diagnostic Panels

CeGaT has launched a diagnostic panel for hereditary childhood liver diseases, and updated its diagnostic panel for epilepsy, metabolic, and brain development disorders.The new diagnostic panel for childhood liver disease was designed in collaboration with Ekkehard Sturm, assistant medical of gastroenterology at the University Children's Hospital, Tübingen. The panel is composed of eight gene sets with 118 genes in total, and offers the rapid and simultaneous analysis of all disease-associated genes known to be causative for hereditary childhood liver diseases. The updated panel for epilepsy, metabolic, and brain development disorders sub-divides  639 relevant genes into 28 gene-subsets according to their clinical importance for the single areas of disease. The latest update includes 265 new genes.

Thermo Fisher Scientific Ion Sequencing Kits

Thermo Fisher Scientific has launched several new sequencing kits: the Ion 520 and 530 ExT Kit-Chef, and the Ion AmpliSeq Direct FFPE DNA Kit. The Ion 520 and 530 ExT Kit-Chef enables robust, automated and fast template preparation  and sequencing of 400 to 600 base-read libraries using the Ion Chef System and the Ion S5 and Ion S5 XL Sequencing Systems, the company said. The kit contains a single-use template and sequencing reagent cartridges with integrated sample tracking which delivers an automated workflow for sequencing of four loaded chips with complete run traceability. The Ion AmpliSeq Direct FFPE DNA Kit enables the preparation of DNA from formalin-fixed paraffin-embedded tissues for library construction using the AmpliSeq protocol without the need for deparaffinization or DNA purification, the company said. The kit is suitable for FFPE tissue sections up to 10 µm thick.

OneOme's RightMed Test

Mayo Clinic spinout OneOme has launched its RightMed test, a 22-gene pharmacogenomic assay intended to be provided as part of routine clinical care. The company said the test can potentially inform treatment decisions across more than 340 medications. OneOme has also developed a platform that allows users to generate a report to guide prescribing using genotype or sequence data obtained elsewhere.

RightMed will be offered through the company's CLIA-registered laboratory in Minneapolis, which it opened in July. OneOme has also entered the market in Puerto Rico, Cuba, and the Dominican Republic through a partnership with High Profile Laboratory in Guaynabo, Puerto Rico.

For more new products and services, please visit the New Products page on our website.